Article
The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice.
Innate immunity - 1 Feb 2013
Richards M Rachel, Black Audrey S, Bonnet David J, Barish Grant D, Woo Connie W, Tabas Ira, Curtiss Linda K, Tobias Peter S
Abstract excerpt
Signaling through MyD88, an adaptor utilized by all TLRs except TLR3, is pro-atherogenic; however, it is unknown whether signaling through TIR-domain-containing adaptor-inducing interferon-β (TRIF), an adaptor used only by TLRs 3 and 4, is relevant to atherosclerosis. We determined that the TRIF(Lps2) lack-of-function mutation was atheroprotective in hyperlipidemic low density lipoprotein (LDL) receptor knockout...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.